Aureus Asset Management LLC Has $8.32 Million Stock Holdings in STERIS plc $STE

Aureus Asset Management LLC grew its position in shares of STERIS plc (NYSE:STE) by 19.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,610 shares of the medical equipment provider’s stock after buying an additional 6,080 shares during the period. Aureus Asset Management LLC’s holdings in STERIS were worth $8,317,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Trust Co. of Vermont boosted its position in shares of STERIS by 30.2% in the fourth quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 38 shares during the period. Bailard Inc. boosted its stake in shares of STERIS by 3.5% in the fourth quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock valued at $283,000 after buying an additional 38 shares during the period. Geneos Wealth Management Inc. grew its position in STERIS by 34.9% during the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 45 shares in the last quarter. Ascent Group LLC grew its position in STERIS by 4.9% during the fourth quarter. Ascent Group LLC now owns 1,009 shares of the medical equipment provider’s stock worth $256,000 after buying an additional 47 shares in the last quarter. Finally, Clear Harbor Asset Management LLC increased its stake in STERIS by 3.8% during the 4th quarter. Clear Harbor Asset Management LLC now owns 1,350 shares of the medical equipment provider’s stock worth $342,000 after acquiring an additional 50 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

STE has been the subject of several analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a report on Thursday, May 21st. KeyCorp reduced their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Finally, Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $278.00.

STERIS Stock Performance

Shares of STE stock opened at $210.65 on Thursday. The firm has a market capitalization of $20.53 billion, a price-to-earnings ratio of 26.56 and a beta of 0.92. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The business’s 50-day moving average price is $211.75 and its 200-day moving average price is $227.97. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the company earned $2.74 EPS. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities research analysts forecast that STERIS plc will post 11.18 EPS for the current year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Insider Activity

In other news, VP John Adam Zangerle sold 1,419 shares of STERIS stock in a transaction on Monday, June 15th. The shares were sold at an average price of $209.28, for a total transaction of $296,968.32. Following the transaction, the vice president owned 35,259 shares in the company, valued at approximately $7,379,003.52. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 3,054 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total transaction of $655,510.56. Following the completion of the sale, the chief executive officer directly owned 65,021 shares in the company, valued at approximately $13,956,107.44. This represents a 4.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 7,328 shares of company stock valued at $1,554,051. Insiders own 1.12% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.